APO Research
Talk to an analyst

APO RESEARCH · REPORT

CAR-T Therapy For B-Cell Malignancies

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global CAR-T Therapy For B-Cell Malignancies Market Outlook and Growth Opportunities 2026

23 December 2025200 pages

Choose your research edition.

Industry ResearchCAR-T Therapy For B-Cell Malignancies Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal CAR-T Therapy For B-Cell Malignancies Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal CAR-T Therapy For B-Cell Malignancies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CAR-T Therapy For B-Cell Malignancies Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal CAR-T Therapy For B-Cell Malignancies Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global CAR-T Therapy For B-Cell Malignancies market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for CAR-T Therapy For B-Cell Malignancies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for CAR-T Therapy For B-Cell Malignancies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for CAR-T Therapy For B-Cell Malignancies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the CAR-T Therapy For B-Cell Malignancies market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the CAR-T Therapy For B-Cell Malignancies market include IMCURE, JW Therapeutics, Johnson And Johnson, Novartis, Roche, CARsgen Therapeutics, Chongqing Precision Biotech, Gilead Sciences and HEBECELL, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global CAR-T Therapy For B-Cell Malignancies market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of CAR-T Therapy For B-Cell Malignancies and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents CAR-T Therapy For B-Cell Malignancies revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global CAR-T Therapy For B-Cell Malignancies market.

CAR-T Therapy For B-Cell Malignancies Segment by Company

IMCURE

JW Therapeutics

Johnson And Johnson

Novartis

Roche

CARsgen Therapeutics

Chongqing Precision Biotech

Gilead Sciences

HEBECELL

Fosun Kite Bio

Legend Biotech

Beihai Biotechnology

AstraZeneca

Regeneron Pharmaceuticals

Kite Pharma

Celgene

Bristol Myers Squibb

Bluebird Bio

CAR-T Therapy For B-Cell Malignancies Segment by Type

Universal CAR-T

Dual Targets CAR-T

Gene Modified Enhanced CAR-T

Multi Targets CAR-T

Single Target CAR-T

CAR-T Therapy For B-Cell Malignancies Segment by Application

Multiple Myeloma

B-Cell Acute Lymphoblastic Leukemia

B-Cell Non-Hodgkin's Lymphoma

Others

CAR-T Therapy For B-Cell Malignancies Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global CAR-T Therapy For B-Cell Malignancies status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the CAR-T Therapy For B-Cell Malignancies key companies, revenue, market share, and recent developments.

3. To split the CAR-T Therapy For B-Cell Malignancies breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions CAR-T Therapy For B-Cell Malignancies market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify CAR-T Therapy For B-Cell Malignancies significant trends, drivers, influence factors in global and regions.

6. To analyze CAR-T Therapy For B-Cell Malignancies competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CAR-T Therapy For B-Cell Malignancies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CAR-T Therapy For B-Cell Malignancies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CAR-T Therapy For B-Cell Malignancies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global CAR-T Therapy For B-Cell Malignancies industry.

Chapter 3: Detailed analysis of CAR-T Therapy For B-Cell Malignancies company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of CAR-T Therapy For B-Cell Malignancies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of CAR-T Therapy For B-Cell Malignancies in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. CAR-T Therapy For B-Cell Malignancies Industry Trends Table 2. CAR-T Therapy For B-Cell Malignancies Industry Drivers Table 3. CAR-T Therapy For B-Cell Malignancies Industry Opportunities and Challenges Table 4. CAR-T Therapy For B-Cell Malignancies Industry Restraints Table 5. Global CAR-T Therapy For B-Cell Malignancies Revenue by Company (US$ Million) & (2021-2026) Table 6. Global CAR-T Therapy For B-Cell Malignancies Revenue Share by Company (2021-2026) Table 7. Global CAR-T Therapy For B-Cell Malignancies Company Ranking, (2024-2026) & (US$ Million) Table 8. Global CAR-T Therapy For B-Cell Malignancies Key Company Manufacturing Base & Headquarters Table 9. Global CAR-T Therapy For B-Cell Malignancies Company, Product Type & Application Table 10. Global CAR-T Therapy For B-Cell Malignancies Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global CAR-T Therapy For B-Cell Malignancies by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Universal CAR-T Table 15. Significant Companies of Dual Targets CAR-T Table 16. Significant Companies of Gene Modified Enhanced CAR-T Table 17. Significant Companies of Multi Targets CAR-T Table 18. Significant Companies of Single Target CAR-T Table 19. Global CAR-T Therapy For B-Cell Malignancies Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global CAR-T Therapy For B-Cell Malignancies Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global CAR-T Therapy For B-Cell Malignancies Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type (2021-2026) Table 23. Global CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Multiple Myeloma Table 25. Significant Companies of B-Cell Acute Lymphoblastic Leukemia Table 26. Significant Companies of B-Cell Non-Hodgkin's Lymphoma Table 27. Significant Companies of Others Table 28. Global CAR-T Therapy For B-Cell Malignancies Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global CAR-T Therapy For B-Cell Malignancies Sales Value by Application (2021-2026) & (US$ Million) Table 30. Global CAR-T Therapy For B-Cell Malignancies Sales Value by Application (2027-2032) & (US$ Million) Table 31. Global CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application (2021-2026) Table 32. Global CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application (2027-2032) Table 33. Global CAR-T Therapy For B-Cell Malignancies Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global CAR-T Therapy For B-Cell Malignancies Sales Value by Region (2021-2026) & (US$ Million) Table 35. Global CAR-T Therapy For B-Cell Malignancies Sales Value Share by Region (2021-2026) Table 36. Global CAR-T Therapy For B-Cell Malignancies Sales Value by Region (2027-2032) & (US$ Million) Table 37. Global CAR-T Therapy For B-Cell Malignancies Sales Value Share by Region (2027-2032) Table 38. Global CAR-T Therapy For B-Cell Malignancies Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global CAR-T Therapy For B-Cell Malignancies Sales Value by Country (2021-2026) & (US$ Million) Table 40. Global CAR-T Therapy For B-Cell Malignancies Sales Value Market Share by Country (2021-2026) Table 41. Global CAR-T Therapy For B-Cell Malignancies Sales Value by Country (2027-2032) & (US$ Million) Table 42. Global CAR-T Therapy For B-Cell Malignancies Sales Value Market Share by Country (2027-2032) Table 43. IMCURE Company Information Table 44. IMCURE Business Overview Table 45. IMCURE CAR-T Therapy For B-Cell Malignancies Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. IMCURE CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 47. IMCURE Recent Development Table 48. JW Therapeutics Company Information Table 49. JW Therapeutics Business Overview Table 50. JW Therapeutics CAR-T Therapy For B-Cell Malignancies Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. JW Therapeutics CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 52. JW Therapeutics Recent Development Table 53. Johnson And Johnson Company Information Table 54. Johnson And Johnson Business Overview Table 55. Johnson And Johnson CAR-T Therapy For B-Cell Malignancies Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Johnson And Johnson CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 57. Johnson And Johnson Recent Development Table 58. Novartis Company Information Table 59. Novartis Business Overview Table 60. Novartis CAR-T Therapy For B-Cell Malignancies Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Novartis CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 62. Novartis Recent Development Table 63. Roche Company Information Table 64. Roche Business Overview Table 65. Roche CAR-T Therapy For B-Cell Malignancies Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Roche CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 67. Roche Recent Development Table 68. CARsgen Therapeutics Company Information Table 69. CARsgen Therapeutics Business Overview Table 70. CARsgen Therapeutics CAR-T Therapy For B-Cell Malignancies Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. CARsgen Therapeutics CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 72. CARsgen Therapeutics Recent Development Table 73. Chongqing Precision Biotech Company Information Table 74. Chongqing Precision Biotech Business Overview Table 75. Chongqing Precision Biotech CAR-T Therapy For B-Cell Malignancies Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Chongqing Precision Biotech CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 77. Chongqing Precision Biotech Recent Development Table 78. Gilead Sciences Company Information Table 79. Gilead Sciences Business Overview Table 80. Gilead Sciences CAR-T Therapy For B-Cell Malignancies Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Gilead Sciences CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 82. Gilead Sciences Recent Development Table 83. HEBECELL Company Information Table 84. HEBECELL Business Overview Table 85. HEBECELL CAR-T Therapy For B-Cell Malignancies Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. HEBECELL CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 87. HEBECELL Recent Development Table 88. Fosun Kite Bio Company Information Table 89. Fosun Kite Bio Business Overview Table 90. Fosun Kite Bio CAR-T Therapy For B-Cell Malignancies Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Fosun Kite Bio CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 92. Fosun Kite Bio Recent Development Table 93. Legend Biotech Company Information Table 94. Legend Biotech Business Overview Table 95. Legend Biotech CAR-T Therapy For B-Cell Malignancies Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. Legend Biotech CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 97. Legend Biotech Recent Development Table 98. Beihai Biotechnology Company Information Table 99. Beihai Biotechnology Business Overview Table 100. Beihai Biotechnology CAR-T Therapy For B-Cell Malignancies Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. Beihai Biotechnology CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 102. Beihai Biotechnology Recent Development Table 103. AstraZeneca Company Information Table 104. AstraZeneca Business Overview Table 105. AstraZeneca CAR-T Therapy For B-Cell Malignancies Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. AstraZeneca CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 107. AstraZeneca Recent Development Table 108. Regeneron Pharmaceuticals Company Information Table 109. Regeneron Pharmaceuticals Business Overview Table 110. Regeneron Pharmaceuticals CAR-T Therapy For B-Cell Malignancies Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 111. Regeneron Pharmaceuticals CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 112. Regeneron Pharmaceuticals Recent Development Table 113. Kite Pharma Company Information Table 114. Kite Pharma Business Overview Table 115. Kite Pharma CAR-T Therapy For B-Cell Malignancies Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 116. Kite Pharma CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 117. Kite Pharma Recent Development Table 118. Celgene Company Information Table 119. Celgene Business Overview Table 120. Celgene CAR-T Therapy For B-Cell Malignancies Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 121. Celgene CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 122. Celgene Recent Development Table 123. Bristol Myers Squibb Company Information Table 124. Bristol Myers Squibb Business Overview Table 125. Bristol Myers Squibb CAR-T Therapy For B-Cell Malignancies Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 126. Bristol Myers Squibb CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 127. Bristol Myers Squibb Recent Development Table 128. Bluebird Bio Company Information Table 129. Bluebird Bio Business Overview Table 130. Bluebird Bio CAR-T Therapy For B-Cell Malignancies Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 131. Bluebird Bio CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 132. Bluebird Bio Recent Development Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources Table 136. Primary Sources List of Figures Figure 1. CAR-T Therapy For B-Cell Malignancies Product Image Figure 2. Global CAR-T Therapy For B-Cell Malignancies Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032) & (US$ Million) Figure 4. Global CAR-T Therapy For B-Cell Malignancies Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Universal CAR-T Image Figure 8. Dual Targets CAR-T Image Figure 9. Gene Modified Enhanced CAR-T Image Figure 10. Multi Targets CAR-T Image Figure 11. Single Target CAR-T Image Figure 12. Global CAR-T Therapy For B-Cell Malignancies Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global CAR-T Therapy For B-Cell Malignancies Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type (2021-2032) Figure 15. Multiple Myeloma Image Figure 16. B-Cell Acute Lymphoblastic Leukemia Image Figure 17. B-Cell Non-Hodgkin's Lymphoma Image Figure 18. Others Image Figure 19. Global CAR-T Therapy For B-Cell Malignancies Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global CAR-T Therapy For B-Cell Malignancies Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application (2021-2032) Figure 22. Global CAR-T Therapy For B-Cell Malignancies Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 23. Global CAR-T Therapy For B-Cell Malignancies Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 24. North America CAR-T Therapy For B-Cell Malignancies Sales Value (2021-2032) & (US$ Million) Figure 25. North America CAR-T Therapy For B-Cell Malignancies Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Europe CAR-T Therapy For B-Cell Malignancies Sales Value (2021-2032) & (US$ Million) Figure 27. Europe CAR-T Therapy For B-Cell Malignancies Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Asia-Pacific CAR-T Therapy For B-Cell Malignancies Sales Value (2021-2032) & (US$ Million) Figure 29. Asia-Pacific CAR-T Therapy For B-Cell Malignancies Sales Value Share by Country (%), 2025 VS 2032 Figure 30. South America CAR-T Therapy For B-Cell Malignancies Sales Value (2021-2032) & (US$ Million) Figure 31. South America CAR-T Therapy For B-Cell Malignancies Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Middle East & Africa CAR-T Therapy For B-Cell Malignancies Sales Value (2021-2032) & (US$ Million) Figure 33. Middle East & Africa CAR-T Therapy For B-Cell Malignancies Sales Value Share by Country (%), 2025 VS 2032 Figure 34. USA CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. USA CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. USA CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Canada CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Canada CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Canada CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Mexico CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Mexico CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Mexico CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Germany CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Germany CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Germany CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. France CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. France CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. France CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. U.K. CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. U.K. CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. U.K. CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Italy CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Italy CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Italy CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Spain CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Spain CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Spain CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Russia CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Russia CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Russia CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Netherlands CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Netherlands CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Netherlands CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Nordic Countries CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Nordic Countries CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Nordic Countries CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. China CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. China CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. China CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Japan CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Japan CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Japan CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. South Korea CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. South Korea CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. South Korea CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. India CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. India CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. India CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Australia CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Australia CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Australia CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Southeast Asia CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Southeast Asia CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Southeast Asia CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Brazil CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Brazil CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Brazil CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Argentina CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Argentina CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Argentina CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Chile CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Chile CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Chile CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Colombia CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Colombia CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Colombia CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Peru CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Peru CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Peru CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Saudi Arabia CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Saudi Arabia CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Saudi Arabia CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Israel CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Israel CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Israel CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. UAE CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. UAE CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. UAE CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Turkey CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Turkey CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Turkey CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Iran CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Iran CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Iran CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Egypt CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Egypt CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Egypt CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Years Considered Figure 119. Research Process Figure 120. Key Executives Interviewed

Scope & coverage.

Types
  • Universal CAR-T
  • Dual Targets CAR-T
  • Gene Modified Enhanced CAR-T
  • Multi Targets CAR-T
  • Single Target CAR-T
Applications
  • Multiple Myeloma
  • B-Cell Acute Lymphoblastic Leukemia
  • B-Cell Non-Hodgkin's Lymphoma
  • Others
Companies covered
  • IMCURE
  • JW Therapeutics
  • Johnson And Johnson
  • Novartis
  • Roche
  • CARsgen Therapeutics
  • Chongqing Precision Biotech
  • Gilead Sciences
  • HEBECELL
  • Fosun Kite Bio
  • Legend Biotech
  • Beihai Biotechnology
  • AstraZeneca
  • Regeneron Pharmaceuticals
  • Kite Pharma
  • Celgene
  • Bristol Myers Squibb
  • Bluebird Bio

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global CAR-T Therapy For B-Cell Malignancies Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 CAR-T Therapy For B-Cell Malignancies Market Dynamics
  1. 2.1 CAR-T Therapy For B-Cell Malignancies Industry Trends
  2. 2.2 CAR-T Therapy For B-Cell Malignancies Industry Drivers
  3. 2.3 CAR-T Therapy For B-Cell Malignancies Industry Opportunities and Challenges
  4. 2.4 CAR-T Therapy For B-Cell Malignancies Industry Restraints
3 CAR-T Therapy For B-Cell Malignancies Market by Company
  1. 3.1 Global CAR-T Therapy For B-Cell Malignancies Company Revenue Ranking in 2025
  2. 3.2 Global CAR-T Therapy For B-Cell Malignancies Revenue by Company (2021-2026)
  3. 3.3 Global CAR-T Therapy For B-Cell Malignancies Company Ranking (2024-2026)
  4. 3.4 Global CAR-T Therapy For B-Cell Malignancies Company Manufacturing Base and Headquarters
  5. 3.5 Global CAR-T Therapy For B-Cell Malignancies Company Product Type and Application
  6. 3.6 Global CAR-T Therapy For B-Cell Malignancies Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global CAR-T Therapy For B-Cell Malignancies Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 CAR-T Therapy For B-Cell Malignancies Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 CAR-T Therapy For B-Cell Malignancies Market by Type
  1. 4.1 CAR-T Therapy For B-Cell Malignancies Type Introduction
  2. 4.1.1 Universal CAR-T
  3. 4.1.2 Dual Targets CAR-T
  4. 4.1.3 Gene Modified Enhanced CAR-T
  5. 4.1.4 Multi Targets CAR-T
  6. 4.1.5 Single Target CAR-T
  7. 4.2 Global CAR-T Therapy For B-Cell Malignancies Sales Value by Type
  8. 4.2.1 Global CAR-T Therapy For B-Cell Malignancies Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global CAR-T Therapy For B-Cell Malignancies Sales Value by Type (2021-2032)
  10. 4.2.3 Global CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type (2021-2032)
5 CAR-T Therapy For B-Cell Malignancies Market by Application
  1. 5.1 CAR-T Therapy For B-Cell Malignancies Application Introduction
  2. 5.1.1 Multiple Myeloma
  3. 5.1.2 B-Cell Acute Lymphoblastic Leukemia
  4. 5.1.3 B-Cell Non-Hodgkin's Lymphoma
  5. 5.1.4 Others
  6. 5.2 Global CAR-T Therapy For B-Cell Malignancies Sales Value by Application
  7. 5.2.1 Global CAR-T Therapy For B-Cell Malignancies Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global CAR-T Therapy For B-Cell Malignancies Sales Value by Application (2021-2032)
  9. 5.2.3 Global CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application (2021-2032)
6 CAR-T Therapy For B-Cell Malignancies Regional Value Analysis
  1. 6.1 Global CAR-T Therapy For B-Cell Malignancies Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global CAR-T Therapy For B-Cell Malignancies Sales Value by Region (2021-2032)
  3. 6.2.1 Global CAR-T Therapy For B-Cell Malignancies Sales Value by Region: 2021-2026
  4. 6.2.2 Global CAR-T Therapy For B-Cell Malignancies Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America CAR-T Therapy For B-Cell Malignancies Sales Value (2021-2032)
  7. 6.3.2 North America CAR-T Therapy For B-Cell Malignancies Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe CAR-T Therapy For B-Cell Malignancies Sales Value (2021-2032)
  10. 6.4.2 Europe CAR-T Therapy For B-Cell Malignancies Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific CAR-T Therapy For B-Cell Malignancies Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific CAR-T Therapy For B-Cell Malignancies Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America CAR-T Therapy For B-Cell Malignancies Sales Value (2021-2032)
  16. 6.6.2 South America CAR-T Therapy For B-Cell Malignancies Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa CAR-T Therapy For B-Cell Malignancies Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa CAR-T Therapy For B-Cell Malignancies Sales Value Share by Country, 2025 VS 2032
7 CAR-T Therapy For B-Cell Malignancies Country-level Value Analysis
  1. 7.1 Global CAR-T Therapy For B-Cell Malignancies Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global CAR-T Therapy For B-Cell Malignancies Sales Value by Country (2021-2032)
  3. 7.2.1 Global CAR-T Therapy For B-Cell Malignancies Sales Value by Country (2021-2026)
  4. 7.2.2 Global CAR-T Therapy For B-Cell Malignancies Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt CAR-T Therapy For B-Cell Malignancies Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt CAR-T Therapy For B-Cell Malignancies Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt CAR-T Therapy For B-Cell Malignancies Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 IMCURE
  2. 8.1.1 IMCURE Company Information
  3. 8.1.2 IMCURE Business Overview
  4. 8.1.3 IMCURE CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (2021-2026)
  5. 8.1.4 IMCURE CAR-T Therapy For B-Cell Malignancies Product Portfolio
  6. 8.1.5 IMCURE Recent Developments
  7. 8.2 JW Therapeutics
  8. 8.2.1 JW Therapeutics Company Information
  9. 8.2.2 JW Therapeutics Business Overview
  10. 8.2.3 JW Therapeutics CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (2021-2026)
  11. 8.2.4 JW Therapeutics CAR-T Therapy For B-Cell Malignancies Product Portfolio
  12. 8.2.5 JW Therapeutics Recent Developments
  13. 8.3 Johnson And Johnson
  14. 8.3.1 Johnson And Johnson Company Information
  15. 8.3.2 Johnson And Johnson Business Overview
  16. 8.3.3 Johnson And Johnson CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Johnson And Johnson CAR-T Therapy For B-Cell Malignancies Product Portfolio
  18. 8.3.5 Johnson And Johnson Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis CAR-T Therapy For B-Cell Malignancies Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Roche
  26. 8.5.1 Roche Company Information
  27. 8.5.2 Roche Business Overview
  28. 8.5.3 Roche CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Roche CAR-T Therapy For B-Cell Malignancies Product Portfolio
  30. 8.5.5 Roche Recent Developments
  31. 8.6 CARsgen Therapeutics
  32. 8.6.1 CARsgen Therapeutics Company Information
  33. 8.6.2 CARsgen Therapeutics Business Overview
  34. 8.6.3 CARsgen Therapeutics CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (2021-2026)
  35. 8.6.4 CARsgen Therapeutics CAR-T Therapy For B-Cell Malignancies Product Portfolio
  36. 8.6.5 CARsgen Therapeutics Recent Developments
  37. 8.7 Chongqing Precision Biotech
  38. 8.7.1 Chongqing Precision Biotech Company Information
  39. 8.7.2 Chongqing Precision Biotech Business Overview
  40. 8.7.3 Chongqing Precision Biotech CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Chongqing Precision Biotech CAR-T Therapy For B-Cell Malignancies Product Portfolio
  42. 8.7.5 Chongqing Precision Biotech Recent Developments
  43. 8.8 Gilead Sciences
  44. 8.8.1 Gilead Sciences Company Information
  45. 8.8.2 Gilead Sciences Business Overview
  46. 8.8.3 Gilead Sciences CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Gilead Sciences CAR-T Therapy For B-Cell Malignancies Product Portfolio
  48. 8.8.5 Gilead Sciences Recent Developments
  49. 8.9 HEBECELL
  50. 8.9.1 HEBECELL Company Information
  51. 8.9.2 HEBECELL Business Overview
  52. 8.9.3 HEBECELL CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (2021-2026)
  53. 8.9.4 HEBECELL CAR-T Therapy For B-Cell Malignancies Product Portfolio
  54. 8.9.5 HEBECELL Recent Developments
  55. 8.10 Fosun Kite Bio
  56. 8.10.1 Fosun Kite Bio Company Information
  57. 8.10.2 Fosun Kite Bio Business Overview
  58. 8.10.3 Fosun Kite Bio CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Fosun Kite Bio CAR-T Therapy For B-Cell Malignancies Product Portfolio
  60. 8.10.5 Fosun Kite Bio Recent Developments
  61. 8.11 Legend Biotech
  62. 8.11.1 Legend Biotech Company Information
  63. 8.11.2 Legend Biotech Business Overview
  64. 8.11.3 Legend Biotech CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Legend Biotech CAR-T Therapy For B-Cell Malignancies Product Portfolio
  66. 8.11.5 Legend Biotech Recent Developments
  67. 8.12 Beihai Biotechnology
  68. 8.12.1 Beihai Biotechnology Company Information
  69. 8.12.2 Beihai Biotechnology Business Overview
  70. 8.12.3 Beihai Biotechnology CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Beihai Biotechnology CAR-T Therapy For B-Cell Malignancies Product Portfolio
  72. 8.12.5 Beihai Biotechnology Recent Developments
  73. 8.13 AstraZeneca
  74. 8.13.1 AstraZeneca Company Information
  75. 8.13.2 AstraZeneca Business Overview
  76. 8.13.3 AstraZeneca CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (2021-2026)
  77. 8.13.4 AstraZeneca CAR-T Therapy For B-Cell Malignancies Product Portfolio
  78. 8.13.5 AstraZeneca Recent Developments
  79. 8.14 Regeneron Pharmaceuticals
  80. 8.14.1 Regeneron Pharmaceuticals Company Information
  81. 8.14.2 Regeneron Pharmaceuticals Business Overview
  82. 8.14.3 Regeneron Pharmaceuticals CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Regeneron Pharmaceuticals CAR-T Therapy For B-Cell Malignancies Product Portfolio
  84. 8.14.5 Regeneron Pharmaceuticals Recent Developments
  85. 8.15 Kite Pharma
  86. 8.15.1 Kite Pharma Company Information
  87. 8.15.2 Kite Pharma Business Overview
  88. 8.15.3 Kite Pharma CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Kite Pharma CAR-T Therapy For B-Cell Malignancies Product Portfolio
  90. 8.15.5 Kite Pharma Recent Developments
  91. 8.16 Celgene
  92. 8.16.1 Celgene Company Information
  93. 8.16.2 Celgene Business Overview
  94. 8.16.3 Celgene CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Celgene CAR-T Therapy For B-Cell Malignancies Product Portfolio
  96. 8.16.5 Celgene Recent Developments
  97. 8.17 Bristol Myers Squibb
  98. 8.17.1 Bristol Myers Squibb Company Information
  99. 8.17.2 Bristol Myers Squibb Business Overview
  100. 8.17.3 Bristol Myers Squibb CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Bristol Myers Squibb CAR-T Therapy For B-Cell Malignancies Product Portfolio
  102. 8.17.5 Bristol Myers Squibb Recent Developments
  103. 8.18 Bluebird Bio
  104. 8.18.1 Bluebird Bio Company Information
  105. 8.18.2 Bluebird Bio Business Overview
  106. 8.18.3 Bluebird Bio CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Bluebird Bio CAR-T Therapy For B-Cell Malignancies Product Portfolio
  108. 8.18.5 Bluebird Bio Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst